We thank the Editor for the opportunity to respond to the letter from Belgard *et al.*^[@bib1]^ In their letter, these authors consider that the issue of ethnic population stratification may have negatively impacted the findings in our original manuscript.^[@bib2]^ We agree that population stratification is an important issue that needs to be accounted for in such analyses.

We wrote to Dr Belgard who kindly provided the 19 single-nucleotide polymorphisms (SNPs) used in their analysis.^[@bib1]^ These 19 SNPs were derived from the 30 SNPs provided in our original article. Of these 19 SNPs, the number of SNPs with positive weights exceeded the number of SNPs with negative weights, including the second most negative weighted SNP, rs12317962, on KCNMB4, which would bias the classifier score. Our original analyses included a total of 237 SNPs. In order to address the issue of ethnic population stratification, we downloaded data from the 1000 genome cohort,^[@bib3]^ including Central European (CEU), Finnish (FIN), Great British (GBR) and Iberian Spanish (IBS) populations.

In their analysis using 19 SNPs, Belgard *et al.* indicated that in Finns (non-autism spectrum disorder (ASD)), our classifier had a higher chance of classifying individuals as ASD compared with CEU (non-ASD) individuals. They concluded that our classifier might be better at separating between European subpopulations than cases from controls. In order to examine this in detail, we tested our classifier performance in correctly identifying control individuals from the CEU, FIN, GBR and IBS control populations. As not all SNPs were available across all data sets, we retrained the classifier using the common SNPs on our training set and then applied the classifier on unseen validation data from the FIN, GBR and IBS control cohorts. Comparing these ethnic European subpopulations, we found that greater differences in classifier score between these populations occurred when only part of the classifier was used (a difference as high as 25% was observed between the FIN and GBR groups). However, using the full classifier, the effects of ethnic population contributed to \<6% of the total difference in classifier score. We also provide the full 237 SNPs relevant to our classifier ([Table 1](#tbl1){ref-type="table"}). The full code used in the generation of the classifier has been made available on the Autism Genetic Resource Exchange (AGRE) website (<http://agre.org>), together with testing of the classifier on other ASD data sets.

Using our SNPs, we then examined their predictive accuracy in classifying control individuals from the FIN and GBR (non-ASD) populations, as well as SFARI (Simons Foundation Autism Research Initiative) ASD probands (the independent validation sample in our paper). We plotted the percentage of individuals classified as ASD against the number of SNPs used in the classifier, with SNPs ordered by absolute magnitude of their weightings. As can be seen in [Figure 1](#fig1){ref-type="fig"}, while population stratification may have an influence at lower SNP numbers with regard to differences in classifier accuracy between populations, such an effect is diminished as a greater number of SNPs are included. The separation in percentage classified as ASD between the SFARI/ASD and the FIN/GBR groups occurred with increasing gradient between 50 and 100 SNPs, whereas at \>150 SNPs the separation between these groups plateaus. This is to be expected, as these SNPs have the smallest weightings within the classifier. Therefore, in keeping with Belgard *et al*\'s analysis, we show that at low SNP numbers, population effects may influence classification accuracy, but these effects are of second order to the ASD signal as the number of SNPs increases.

Using the classifier, as described above, we tested its accuracy in correctly classifying controls (non-ASD) within individual European cohorts. We achieved accuracies (that is, correct classification as non-ASD) of 82% for the FIN, 78% for GBR and 67% for the Spanish cohorts. In addition, to determine classifier performance confidence intervals, we performed a bootstrap analysis (1000 permutations were undertaken; 80% of the data was used to train a classifier to predict the remaining 20%) on all white non-hispanic populations, including all available populations (that is, SFARI and Autism Genetic Resource Exchange probands, and WTBC, CEU, FIN, GBR and IBS Controls). Diagnostic accuracy for ASD was 66.0% (90% CI: 61.5--71.9), with a sensitivity of 63.4% (90% CI: 54.3--75.9) and specificity of 67.2% (90% CI: 59.5--74.3). This equates to a positive likelihood ratio of 1.9 (90% CI: 1.3--3.0).

In our paper, we reported positive and negative predictive accuracies that were 70.8% and 71.8%, respectively.^[@bib2]^ Based on a population prevalence of 1:88 cases of ASD in the US population,^[@bib4]^ this equates to a positive predictive value (that is, precision) of 2.8% and a negative predictive value of 99.5%. This suggests that the classifier is not suitable as a general screening method, rather it should only be considered in high-risk populations where the base rate of ASD is high and produces acceptable positive and negative predictive values.

In conclusion, we demonstrate that the SNPs in our classifier show some ability to non-randomly distinguish between ASD and controls and that our results are not merely explained by population stratification as demonstrated in our analyses in independent cohorts of individuals of European ancestry. Further work on such approaches is needed in order to validate these findings, for example, prospective studies that examine children at risk for ASD (such as families with an affected member).

We thank Dr Belgard for his helpful suggestions and feedback on further analyses in the preparation of this letter.

A patent application has been filed by The University of Melbourne.

![Percentage of individuals classified as ASD as a function of the number of single-nucleotide polymorphisms (SNPs) ordered in decreasing absolute magnitude. Significant variance was observed at smaller number of SNPs (not plotted). Note the gradient differential between SFARI cases versus FIN and GBR between SNPs 80 and 150. ASD, autism spectrum disorder; SNPs, single-nucleotide polymorphisms; SFARI-CASES, Simons Foundation Autism Research Initiative ASD probands; population samples from the 1000 genome cohort^[@bib3]^: GBR, Great British; FIN, Finnish.](mp2013186f1){#fig1}

###### List of all 237 SNPs for ASD classifier in the CEU Cohort,^[@bib2]^ organised from highest to lowest median weightings

  *SNP*        *Weight lower*   *Weight median*   *Weight upper*   *Gene no.*   *Gene symbol*
  ------------ ---------------- ----------------- ---------------- ------------ ---------------
  rs968122     1.5465           1.5555            1.5645           27345        *KCNMB4*
  rs876619     0.9476           1.2092            1.4708           2775         *GNAO1*
  rs11020772   0.8553           0.8641            0.8729           2915         *GRM5*
  rs9288685    0.5856           0.5998            0.614            3635         *INPP5D*
  rs10193128   0.5836           0.5946            0.6056           3635         *INPP5D*
  rs7842798    0.5298           0.5386            0.5474           114          *ADCY8*
  rs3773540    0.5125           0.5208            0.5291           55799        *CACNA2D3*
  rs1818106    0.5002           0.5161            0.532            80310        *PDGFD*
  rs2384061    0.4195           0.4306            0.4417           109          *ADCY3*
  rs12582971   0.3983           0.4295            0.4607           5288         *PIK3C2G*
  rs10409541   0.4067           0.4189            0.4311           773          *CACNA1A*
  rs2300497    0.3782           0.3889            0.3996           801          *CALM1*
  rs7562445    0.3741           0.3843            0.3945           2066         *ERBB4*
  rs7313997    0.3382           0.3567            0.3752           5801         *PTPRR*
  rs2239118    0.3348           0.3552            0.3756           775          *CACNA1C*
  rs4688054    0.1801           0.3476            0.515            2932         *GSK3B*
  rs10823195   0.2597           0.3445            0.4294           1763         *DNA2*
  rs9798267    0.2759           0.3388            0.4017           84083        *ZRANB3*
  rs1075354    0.4236           0.3177            0.6402           55799        *CACNA2D3*
  rs1942052    0.2641           0.3088            0.3535           130013       *ACMSD*
  rs4696443    0.2525           0.3047            0.3569           23321        *TRIM2*
  rs243196     0.2402           0.2976            0.3549           1112         *FOXN3*
  rs16929470   0.1854           0.2712            0.3571           775          *CACNA1C*
  rs7580690    0.1647           0.2248            0.285            83439        *TCF7L1*
  rs7145618    0.1515           0.2238            0.296            5528         *PPP2R5C*
  rs3770132    0.1514           0.2093            0.2673           3676         *ITGA4*
  rs3790095    0.1215           0.2017            0.2819           2775         *GNAO1*
  rs1013459    0.1417           0.1969            0.2522           2774         *GNAL*
  rs11001056   0.1519           0.1891            0.2263           5592         *PRKG1*
  rs10952662   0.148            0.1868            0.2257           26047        *CNTNAP2*
  rs7756516    0.152            0.1853            0.2186           3120         *HLA-DQB2*
  rs8054767    0.1322           0.1803            0.2284           5579         *PRKCB*
  rs2239028    0.1121           0.1763            0.2405           775          *CACNA1C*
  rs3935743    0.0969           0.1737            0.2505           5336         *PLCG2*
  rs1928168    0.0657           0.099             0.1322           401237       *LINC00340*
  rs7100765    0.0434           0.0935            0.1436           5593         *PRKG2*
  rs1369450    0.0563           0.0924            0.1285           114          *ADCY8*
  rs1040336    −0.0615          0.091             0.2435           2272         *FHIT*
  rs10407144   0.0434           0.0872            0.131            773          *CACNA1A*
  rs10794197   0.045            0.0869            0.1287           1488         *CTBP2*
  rs3734464    0.0247           0.0868            0.149            5071         *PARK2*
  rs7864216    −0.0072          0.0863            0.1798           9630         *GNA14*
  rs4254056    0.0432           0.0846            0.126            338751       *OR52L1*
  rs988920     0.0453           0.0842            0.1232           9229         *DLGAP1*
  rs12393998   0.0536           0.0839            0.1142           8450         *CUL4B*
  rs872794     0.0413           0.0813            0.1213           3778         *KCNMA1*
  rs2503220    −0.0527          0.0806            0.214            5142         *PDE4B*
  rs10468681   0.0356           0.08              0.1243           2774         *GNAL*
  rs7258489    0.0428           0.079             0.1152           808          *CALM3*
  rs153968     0.0379           0.0765            0.115            5144         *PDE4D*
  rs944761     0.0361           0.076             0.1159           9568         *GABBR2*
  rs2161630    0.0232           0.0754            0.1276           10725        *NFAT5*
  rs7097311    0.0294           0.0703            0.1111           5593         *PRKG2*
  rs2088747    −0.0137          0.0693            0.1522           11060        *WWP2*
  rs9832697    −0.0766          0.0689            0.2144                        *KCNMB2*
  rs7731023    0.0343           0.0683            0.1023           6502         *SKP2*
  rs7120612    0.0224           0.0659            0.1094           390055       *OR52A6*
  rs2033655    0.0277           0.0647            0.1017           109          *ADCY3*
  rs1453541    −0.1057          0.0354            0.1766           219983       *OR4D6*
  rs3746821    −0.0262          0.0335            0.0932           958          *CD40*
  rs220740     −0.0085          0.0332            0.0749           10846        *PDE10A*
  rs2299679    −0.014           0.0331            0.0801           5332         *PLCB4*
  rs887387     −0.0028          0.0317            0.0662           489          *ATP2A3*
  rs7174459    −0.0092          0.0288            0.0669           4735         *NEDD5*
  rs884399     −0.0073          0.0281            0.0634           5581         *PRKCE*
  rs5021051    −0.0146          0.027             0.0686           2895         *GRID2*
  rs2903813    −0.0208          0.0252            0.0711           3315         *HSPB1*
  rs1062935    −0.0207          0.0245            0.0697           57521        *RPTOR*
  rs9347553    −0.0154          0.0228            0.0609           5071         *PARK2*
  rs11072416   −0.0259          0.0222            0.0703           6263         *RYR3*
  rs4553343    −0.0304          0.0204            0.0712           2977         *GUCY1A2*
  rs7146234    −0.0132          0.0202            0.0535           5495         *PPM1A*
  rs848282     −0.0191          0.0172            0.0536           55120        *FANCL*
  rs7962764    −0.0495          0.0126            0.0748           5801         *PTPRR*
  rs12726519   −0.0377          0.0098            0.0572           5321         *PLA2G4A*
  rs718949     −0.0303          0.0093            0.0489           1488         *CTBP2*
  rs1954787    −0.0264          0.0089            0.0441           2900         *GRIK4*
  rs2238079    −0.0283          0.0084            0.045            775          *CACNA1C*
  rs1337420    −0.0398          0.008             0.0558           2898         *GRIK2*
  rs917948     −0.0553          0.0075            0.0704           5536         *PPP5C*
  rs3817222    −0.1848          0.0055            0.1957           4660         *PPP1R12B*
  rs17531147   −0.0612          0.003             0.0672           55970        *GNG12*
  rs11048476   −0.0801          −0.0384           0.0033           3709         *ITPR2*
  rs4145903    −0.0762          −0.0395           −0.0028          783          *CACNB2*
  rs10505029   −0.1011          −0.0404           0.0203           51366        *UBR5*
  rs1122838    −0.1213          −0.0408           0.0396           9630         *GNA14*
  rs1993477    −0.0818          −0.0434           −0.0049          51366        *UBR5*
  rs2179871    −0.0912          −0.0454           0.0005           10369        *CACNG2*
  rs10740244   −0.0892          −0.0467           −0.0041          5592         *PRKG1*
  rs2503220    −0.1151          −0.0472           0.0207           5142         *PDE4B*
  rs1065657    −0.0838          −0.0488           −0.0139          51465        *UBE2J1*
  rs12714137   −0.1234          −0.0528           0.0179           83439        *TCF7L1*
  rs7176475    −0.1275          −0.0537           0.0201           123746       *PLA2G4E*
  rs1937671    −0.0953          −0.0545           −0.0138          5592         *PRKG1*
  rs7079293    −0.0902          −0.0549           −0.0196          10581        *SORBS2*
  rs1003854    −0.1288          −0.0551           0.0187           326          *AIRE*
  rs919741     −0.0962          −0.0565           −0.0169          815          *CAMK2A*
  rs750438     −0.1075          −0.0574           −0.0074          11184        *MAP4K1*
  rs6139034    −0.0997          −0.0576           −0.0154          3704         *ITPA*
  rs1554606    −0.1087          −0.0599           −0.0111          6018         *IL6*
  rs7108524    −0.0938          −0.0603           −0.0267          81286        *OR51E3*
  rs1002424    −0.1023          −0.0626           −0.0229          5562         *PRKAA1*
  rs2239316    −0.1033          −0.0631           −0.0228          1387         *CREBBP*
  rs5030949    −0.157           −0.0653           0.0264           3098         *HK1*
  rs17682073   −0.1006          −0.066            −0.0315          6262         *RYR2*
  rs1872902    −0.1108          −0.0665           −0.0221          80310        *PDGFD*
  rs11602535   −0.166           −0.1236           −0.0812          219981       *OR5A2*
  rs11644436   −0.1733          −0.1253           −0.0774          5336         *PLCG2*
  rs10762342   −0.1909          −0.1283           −0.0658          5592         *PRKG1*
  rs11583646   −0.2023          −0.1311           −0.0599          6262         *RYR2*
  rs6118611    −0.1819          −0.1321           −0.0822          5332         *PLCB4*
  rs2587891    −0.1722          −0.1322           −0.0922          2775         *GNA01*
  rs4651343    −0.1739          −0.1333           −0.0926          5321         *PLA2G4A*
  rs1659506    −0.1761          −0.1363           −0.0966          23295        *MGRN1*
  rs2271986    −0.1968          −0.1367           −0.0767          4842         *NOS1*
  rs2302898    −0.1775          −0.1375           −0.0975          10381        *TUBB3*
  rs6971999    −0.2088          −0.1425           −0.0763          26212        *OR2F2*
  rs2272197    −0.1896          −0.1485           −0.1073          4216         *MAP3K4*
  rs4947963    −0.1867          −0.1493           −0.1119          1956         *EGFR*
  rs7536307    −0.1876          −0.1507           −0.1138          26289        *AK5*
  rs12462609   −0.2085          −0.151            −0.0936          773          *CACNA1A*
  rs1517521    −0.2925          −0.152            −0.0114          23180        *RFTN1*
  rs8063461    −0.1865          −0.1534           −0.1203          7249         *TSC2*
  rs888817     −0.1937          −0.1604           −0.1272          5924         *RASGRF2*
  rs922445     −0.2435          −0.1659           −0.0883          2775         *GNAO1*
  rs339408     −0.203           −0.167            −0.131           9322         *TRIP10*
  rs7512378    −0.2068          −0.1691           −0.1314          55811        *ADCY10*
  rs7870040    −0.2408          −0.1892           −0.1376          774          *CACNA1B*
  rs3904668    −0.2423          −0.2069           −0.1715          29993        *PACS1N1*
  rs12716928   −0.2784          −0.2073           −0.1362          5336         *PLCG2*

Abbreviations: ASD, autism spectrum disorder; CEU, Central European; SNP, single-nucleotide polymorphism.

Weight indicates the contribution of each SNP to ASD clinical status. The lower and upper weights represent the 95% confidence intervals (CIs) of the distribution of weights for each SNP.
